Leukemia

Published by: Nature Publishing Group  

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Scheinberg
    Scheinberg
  3. Levine
    Levine
  4. Papaemmanuil
    Papaemmanuil
  5. Tallman
    Tallman
  6. Berman
    Berman
  7. Clarkson
    Clarkson
  8. Diamond
    Diamond
  9. Kentsis
    Kentsis
  10. O'Reilly
    O'Reilly

Groups

  1. Tow Center for Developmental Oncology (TCDO) (67)
  2. GSK Faculty (64)
  3. Center for Hematologic Malignancies (60)
  4. Department of Medicine (55)
  5. Hematologic Malignancies, Division of (50)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (46)
  7. Executive Committee, Center for Hematologic Malignancies (38)
  8. Adult Leukemia (36)
  9. Sloan Kettering Institute Faculty (26)
  10. Hematologic Malignancies Research (25)
Search Within
  1. "Tow Center for Developmental Oncology (TCDO) "
Formats
  1. Journal Article (57)
  2. Research Letter (6)
  3. Editorial (2)
  4. Correspondence (1)
  5. Meeting Abstract (1)
Groups
  1. Tow Center for Developmental Oncology (TCDO) (67)
  2. GSK Faculty (64)
  3. Center for Hematologic Malignancies (60)
  4. Department of Medicine (55)
  5. Hematologic Malignancies, Division of (50)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (46)

More Groups

People
  1. Omar Abdel-Wahab (29)
  2. David Scheinberg (18)
  3. Ross Levine (16)
  4. Jay Patel (9)
  5. Elli Papaemmanuil (8)
  6. Peter Maslak (5)

More People

Years
  1. 2025 (4)
  2. 2024 (1)
  3. 2023 (3)
  4. 2022 (4)
  5. 2021 (4)
  6. 2020 (1)

More Years

Publishers
  1. Nature Publishing Group (67)

Results (67)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms
    Journal Article

    Thier, J.; Hofmann, S.; Kirchhof, K. M.; Todisco, G.; Mortera-Blanco, T.; Lilienthal, I.; Kanellis, D. C.; Barbosa, I.; Björklund, A. C.; Deslauriers, A. G.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
    Research Letter

    Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A.; Sallman, D.; Patel, M.; Stevens, D.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms
    Correspondence

    Salmon-Divon, M.; Meyuchas, R.; Shpilberg, O.; Okon, E.; Benhamida, J.; Yabe, M.; Petrova-Drus, K.; Zvida-Bloch, T.; Basood, M.; Mazor, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma
    Journal Article

    Shaw, T. I.; Pounds, S.; Cao, X.; Ma, J.; Palacios, G.; Mason, J.; Perkins, S.; Wu, G.; Fan, Y.; Wang, J.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis
    Research Letter

    Sui, P.; Ge, G.; Chen, S.; Bai, J.; Rubalcava, I. P.; Yang, H.; Guo, Y.; Zhang, P.; Li, Y.; Medina, E. A.; more...
    Leukemia (2024)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Research Letter

    Bewersdorf, J. P.; Stahl, M.; Taylor, J.; Mi, X.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Lu, S. X.; Bourcier, J.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
    Journal Article

    Willekens, C.; Laplane, L.; Dagher, T.; Benlabiod, C.; Papadopoulos, N.; Lacout, C.; Rameau, P.; Catelain, C.; Alfaro, A.; Edmond, V.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Finding consistency in classifications of myeloid neoplasms: A perspective on behalf of the International Workshop for Myelodysplastic Syndromes
    Editorial

    Zeidan, A. M.; Bewersdorf, J. P.; Buckstein, R.; Sekeres, M. A.; Steensma, D. P.; Platzbecker, U.; Loghavi, S.; Boultwood, J.; Bejar, R.; Bennett, J. M.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
    Research Letter

    Rasmussen, B.; Göhring, G.; Bernard, E.; Nilsson, L.; Tobiasson, M.; Jädersten, M.; Garelius, H.; Dybedal, I.; Grønbaek, K.; Ejerblad, E.; more...
    Leukemia (2022)

    Fulltext@MSK | Save

    • Leukemia – authorized name for:

    Name ISSN / ISBN Publisher
    Leukemia 08876924 2020, The Author(s)
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2018, The Author(s)
    Leukemia 08876924 The Author(s), Under Exclusive Licence To Springer Nature Limited 2024
    Leukemia 08876924 The Author(s) 2024
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 14765551 Unknown
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 Nature Publishing Group
    Leukemia 08876924 2018, Springer Nature Limited
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 14765551 Macmillan Publishers Limited
    Leukemia 08876924 2023, The Author(s), Under Exclusive Licence To Springer Nature Limited
    Leukemia 08876924 Unknown
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2020, The Author(s), Under Exclusive Licence To Springer Nature Limited
    Leukemia 08876924 2019, Springer Nature Limited
    Leukemia 0887-6924 Unknown
    Leukemia 0887-6924 Stockton Press
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2021, The Author(s)
    Leukemia 08876924 2021, The Author(s), Under Exclusive Licence To Springer Nature Limited
    Leukemia 08876924 2023, The Author(s)
    Leukemia 08876924 The Author(s) 2018
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2019, The Author(s)
    Leukemia 08876924 Macmillan Publishers Limited
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2018, Macmillan Publishers Limited, Part of Springer Nature
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2022, The Author(s), Under Exclusive Licence To Springer Nature Limited
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 2022, The Author(s)
    Leukemia 08876924 The Author(s), Under Exclusive Licence To Springer Nature Limited 2023
    Leukemia 08876924 The Author(s)
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Macmillan Publishers Limited
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 0887-6924 Nature Publishing Group
    Leukemia 08876924 The Author(s), Under Exclusive Licence To Springer Nature Limited 2025
    Leukemia 08876924 The Author(s) 2025
    Leukemia 08876924 Macmillan Publishers Limited
    Leukemia (08876924) 2168-6181 Unknown
    Leukemia (08876924) 0732-183X Unknown
    Leukemia (08876924) 0887-6924 Unknown
    Leukemia (Basingstoke) 0887-6924 Unknown